Full-Time

Business Development Director

Updated on 9/4/2026

Perceptive

Perceptive

1,001-5,000 employees

Imaging core labs and eClinical solutions

Compensation Overview

€90k - €110k/yr

+ Sales Incentive Plan

Remote in Germany

Remote

Remote within Germany.

Bachelor's, MBA

Category
Sales & Account Management (1)
Required Skills
Sales
Lead Generation
Forecasting
Marketing

Get referred to Perceptive

See people who can refer or advise you

Requirements
  • Proven track record of success in sales within life sciences (CRO, eClinical, clinical technology or related)
  • Demonstrable success building and executing territory and account strategies
  • Strong history of delivering revenue growth and exceeding targets
  • Experience managing complex sales cycles, including proposal development and bid leadership
  • Ability to identify pipeline risks and implement mitigation strategies
  • Bachelor’s degree in Business, Life Sciences, or related field (MBA preferred)
  • Fluent in English and German
Responsibilities
  • Meet and exceed annual sales targets set by Commercial leadership
  • Own revenue delivery across your assigned territory/accounts
  • Build and execute strategic territory and account plans aligned to company growth objectives
  • Identify and pursue high-value opportunities to consistently grow revenue
  • Develop and maintain a strong, qualified sales pipeline
  • Proactively manage pipeline health, risks, and forecasting accuracy
  • Collaborate with Lead Generation and senior Commercial stakeholders to identify and pursue new opportunities
  • Lead strategic client engagement from initial approach through to deal close
  • Own proposal strategy, including narrative development and executive positioning
  • Lead bid pursuit processes, governance meetings, and cross-functional deal teams
  • Build strong, long-term relationships to establish preferred supplier status
  • Drive account expansion through strategic account planning
  • Identify opportunities to increase wallet share within existing clients
  • Work with Strategic Marketing and internal teams to introduce new eClinical offerings into the market
  • Support successful go-to-market execution for new capabilities
Desired Qualifications
  • MBA preferred
  • Familiarity with Salesforce or other CRM platforms (desirable)
  • MBA preferred is already included; avoid duplication

Generate a clear, concise company summary for Perceptive based on the provided description.

Company Size

1,001-5,000

Company Stage

Late Stage VC

Total Funding

$15M

Headquarters

New Haven, Connecticut

Founded

2000

Get referred to Perceptive

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Perceptive Discovery launched α-Sight in April 2026 with MH3D, targeting oncology radioligands.
  • January 2026 brought $15 million for At-211 infrastructure across U.S. and U.K. sites.
  • April 2026 Trialzen and Kayentis alliances broaden Perceptive eClinical's commercialization and integration reach.

What critics are saying

  • Palantir's 2026 lawsuit against Percepta AI highlights talent-poaching and confidentiality vulnerability.
  • WCG and other imaging consolidators keep compressing Perceptive's core-lab pricing power.
  • If Perceptive misses alpha-imaging execution, CapVest's 2026 investment stops scaling returns.

What makes Perceptive unique

  • Perceptive spans discovery, imaging, and RTSM across one R&D workflow.
  • Its 2026 α-Sight partnership adds rare alpha-radiopharmaceutical imaging for Actinium-225 and Astatine-211.
  • Perceptive's 50-year lineage and 400-plus approvals signal embedded regulatory credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Remote Work Options

Health Savings Account/Flexible Spending Account

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Adoption Assistance

Paid Holidays

Parental Leave

Education allowance

Tuition Reimbursement

Meal Benefits

Cycle to work scheme

Season ticket loan

Cycle to work scheme

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Apr 15th, 2026
Perceptive Discovery partners with MH3D to launch α-Sight™ for alpha radiopharmaceutical imaging

Perceptive Discovery has partnered with MH3D to launch α-Sight™, a preclinical imaging service for visualising alpha-emitting radiopharmaceuticals. The offering addresses imaging limitations in alpha-emitting therapies, which are increasingly used in oncology, by providing high-sensitivity, quantitative whole-body imaging. α-Sight™ combines MH3D's Alpha-SPECT™ Mini platform with Perceptive Discovery's expertise in preclinical imaging and radiochemistry. The service supports multi-isotope imaging for therapies using Actinium-225 and Astatine-211, integrated with VivoQuant™ for advanced analysis. Perceptive Discovery will serve as MH3D's exclusive service provider whilst collaborating on product enhancements. The platform supports biodistribution studies, tumour targeting validation and pharmacokinetic assessment to accelerate radioligand therapy development.

PR Newswire
Jan 8th, 2026
Perceptive Discovery secures $15M to expand radiochemistry and cell assay capabilities

Perceptive Discovery, the preclinical services division of Perceptive, has announced $15 million in strategic investments from shareholder CapVest Partners to expand its radiochemistry, cell assay and in vitro biology capabilities. The funding will support development services for oncology and radiopharmaceutical programmes from discovery through early clinical translation. The investment will significantly expand Perceptive Discovery's Astatine-211 infrastructure globally across two sites in the US and UK. The new facilities will feature specialised research environments and dedicated scientific personnel to support At-211 labelling, method development and preclinical applications. The investment underscores CapVest's confidence in Perceptive Discovery's business potential and reinforces the company's commitment to delivering integrated, high-quality preclinical workflows for drug development programmes.